價格 | 詢價 |
包裝 | 5mg/50mg/200mg |
最小起訂量 | 5mg/50mg/200mg |
發(fā)貨地 | 上海 |
更新日期 | 2012-05-28 |
中文名稱:Foretinib | 英文名稱:Foretinib |
CAS:849217-64-7 | 有效期: 一年 |
Foretinib (GSK1363089, XL880) is a novel MET and VEGFR2/KDR kinases inhibitor with an IC50 of 0.4 and 0.8 nM for MET and KDR, respectively. Foretinib (GSK1363089, XL880) inhibits HGF receptor family tyrosine kinases with an IC50 of 3 nM for Ron. Foretinib (GSK1363089, XL880) also inhibits KDR, Flt-1, and Flt-4 with IC50 of 0.9, 6.8 and 2.8 nM, respectively. In addition, EXEL-2880 inhibits members of the platelet-derived growth factor receptor family and the angiopoietin-1 receptor Tie-2. Foretinib (GSK1363089, XL880) exhibits modest activity against fibroblast growth factor receptor 1 and epidermal growth factor receptor and is inactive against 50 serine/threonine kinases, including cyclin-dependent kinases and protein kinase C isoforms. To delineate the cellular effect of foretinib (GSK1363089, XL880), VEGF- induced extracellular signal-regulated kinase phosphorylation was used to assess the effect of the compound on phosphorylation of KDR in human umbilical vein endothelial cells that resulted in an IC50 of 16 nM. Foretinib(GSK1363089, XL880) is the 1st orally available small molecule inhibitor of Met to enter the clinic and appears to be generally well tolerated. Anti-tumor activity has been observed and Foretinib may represent an active treatment option for patients with papillary renal-cell carcinoma.
成立日期 | 2006-10-16 (19年) | 注冊資本 | 1000萬人民幣 |
員工人數(shù) | 年?duì)I業(yè)額 | ||
主營行業(yè) | 經(jīng)營模式 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP6年
|
上海澤葉生物科技有限公司
|
2025-01-20 | |
¥1036.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-01-20 | |
詢價 |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 | |
¥342 |
VIP12年
|
上海陶術(shù)生物科技有限公司
|
2024-12-02 | |
¥1109.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
詢價 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
詢價 |
武漢貝爾卡生物醫(yī)藥有限公司
|
2014-08-15 | ||
詢價 |
生物快車
|
2014-08-14 | ||
詢價 |
Biotool LLC
|
2012-05-28 | ||
詢價 |
Selleckchem LLC
|
2012-05-28 |